Radiochemotherapy and brachytherapy could be the standard treatment for anal canal cancer in elderly patients? A retrospective single-centre analysis

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Lestrade, Laetitia ^a   De Bari, Berardino ^b   Montbarbon, Xavier ^a   Pommier, Pascal ^a   Carrie, Christian ^a  

^a CENTRE LÉON BÉRARD   (France)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Anal canal cancer; Brachytherapy; Elderly patients; Radiochemotherapy; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; FLUOROURACIL; MITOMYCIN;

AGED; ANUS CANCER; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BRACHYTHERAPY; CANCER INCIDENCE; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; DISEASE SPECIFIC SURVIVAL; FEMALE; GASTROINTESTINAL TOXICITY; GERIATRIC PATIENT; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; NEPHROTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANUS NEOPLASMS; BRACHYTHERAPY; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84872117296     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0402-x     Document Type: Article

References (35)

1. Halperin EC, Perez CA, Brady LW. Perez and Brady's principles and practice of radiation oncology. 5th ed. Chapter 59 - Anal Cancer. 2008. p. 1386.
2. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer. 1997;80:1273-83.
3. Yancik R, Ries LA. Cancer in older persons: an international issue in an aging world. Semin Oncol. 2004;31:128-36.
4. Monfardini S, Falci C, Brunello A, et al. Cancer in the elderly. Intern Emerg Med. 2011;6(Suppl 1):115-8.
5. Niyazi M, Schwarz SB, Suchorska B, et al. Radiotherapy with and without temozolomide in elderly patients with glioblastoma. Strahlenther Onkol. 2012;188(2):154-9.
6. Firat S, Bousamra M, Gore E, et al. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;52:1047-57.
7. Rochon PA, Katz JN, Morrow LA, et al. Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability. A prospective comparison of three comorbidity indices. Med Care. 1996;34:1093-101.
8. Satariano WA, Ragland DA. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994;120:104-10.
9. Extermann M, Aapro M, Bernabei R, et al. Task force on CGA of the International Society of Geriatric Oncology. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55:241-52.
10. Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol. 2000;35(3):181-200.
11. Allal AS, Obradovic M, Laurencet F, et al. Treatment of anal carcinoma in the elderly feasibility and outcome of radical radiotherapy with or without concomitant chemotherapy. Cancer. 1999;85(1):26-31.
12. Charnley N, Choudhury A, Chesser P, et al. Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy. Br J Cancer. 2005;92:1221-5.
13. De Bari B, Lestrade L, Chekrine T, et al. Should the treatment of anal carcinoma be adapted in the elderly? A retrospective analysis of acute toxicities in a French centre and a review of the literature. Cancer Radiother. 2012;16(1):52-7. Article in French.
14. Fallai C, Cerrotta A, Valvo F, et al. Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy. Crit Rev Oncol Hematol. 2007;61:261-8.
15. Saarilahti K, Arponen P, Vaalavirta L, et al. Chemoradiotherapy of anal cancer is feasible in elderly patients: treatment results of mitomycin-5-FU combined with radiotherapy at Helsinki University Central Hospital 1992-2003. Acta Oncol. 2006;45(6):736-42.
16. Valentini V, Morganti AG, Luzi S, et al. Is chemoradiation feasible in elderly patients? Cancer. 1997;80:1387-92.
17. National Cancer Institute. Common terminology criteria for adverse events (CTCAE), version 4.0. 2009 May. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03- 2010-06-14-QuickReference-5x7.pdf.
18. Womack NR, Morrison JF, Williams NS. Prospective study of the effects of postanal repair in neurogenic faecal incontinence. Br J Surg. 1988;75:48-52.
19. Zekrya D, Loures Valle BH, Lardia C, et al. Geriatrics index of comorbidity was the most accurate predictor of death in geriatric hospital among six comorbidity scores. J Clin Epidemiol. 2010;63(9):1036-44.
20. Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245-51.
21. Chapet O, Gerard JP, Riche B, Alessio A, Mornex F, Romestaing P. Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer. Int J Radiat Oncol Biol Phys. 2005;63(5):1316-24.
22. Giordano FA, Wenz F. Negative influence of undertreatment in elderly patients with breast cancer. Strahlenther Onkol. 2012;188(6):527-8. German.
23. Djunic I, Virijevic M, Novkovic A, Djurasinovic V, Colovic N, Vidovic A, Suvajdzic-Vukovic N, Tomin D. Comorbidity as a risk factor for overall survival and decision criteria for intensity of chemotherapy in elderly patients with acute myeloid leukemia. Med Oncol. 2012;29(2):1077-81. [Epub 2011 Feb 18].
24. Irvin TT. Prognosis of colorectal cancer in the elderly. Br J Surg. 1988;75:419-21.
25. Karl RC, Smith SK, Fabri PJ. Validity of major cancer operations in elderly patients. Ann Surg Oncol. 1995;2(107-13):19-21.
26. Balducci M, Fiorentino A, De Bonis P, et al. Impact of age and co-morbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies. Med Oncol. 2012;29(5):3478-83.
27. Papillon J, Montbarbon JF. Epidermoid carcinoma of the anal canal. A series of 279 cases. Dis Colon Rectum. 1987;30(5):324-33.
28. Sandhu AP, Symonds RP, Robertson AG, et al. Interstitial iridium-192 implantation combined with external radiotherapy in anal cancer: ten years experience. Int J Radiat Oncol Biol Phys. 1998;40(3):575-81.
29. Crowley C, Winship AZ, Hawkins MA, et al. Size does matter: can we reduce the radiotherapy field size for selected cases of anal canal cancer undergoing chemoradiation? Clin Oncol (R Coll Radiol). 2009;21(5):376-9.
30. Guckenberger M, Ok S, Polat B, et al. Toxicity after intensity modulated, image-guided radiotherapy for prostate cancer. Strahlenther Onkol. 2010;186(10):535-43.
31. Sanguineti G, Endres EJ, Sormani MP, et al. Dosimetric predictors of diarrhea during radiotherapy for prostate cancer. Strahlenther Onkol. 2009;185(6):390-6.
32. Treutwein M, Hipp M, Kölbl O, et al. IMRT of prostate cancer: a comparison of fluence optimization with sequential segmentation and direct step-and-shoot optimization. Strahlenther Onkol. 2009;185(6):379-83.
33. Fiorino C, Valdagni R, Rancati T, et al. Dose-volume effects for normal tissues in external radiotherapy: pelvis. Radiother Oncol. 2009;93(2):153-67.
34. Milano MT, Jani AB, Farrey KJ, et al. Intensity modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2005;63:354-61.
35. Saarilahti K, Arponen P, Vaalavirta L, et al. The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol. 2008;87(3):383-90.